HCC | Clinical

Investigating TACE With Nivolumab in Hepatocellular Carcinoma

October 12, 2021

Arndt Vogel, MD, discusses the trial design of IMMUTACE, which is evaluating the efficacy of transarterial chemoembolization in combination with nivolumab for the treatment of intermediate-stage hepatocellular carcinoma.

Vogel Discusses Real-World Survival Data of Immunotherapy in HCC

October 10, 2021

Arndt Vogel, MD, the managing senior consultant and professor in the department of Gastroenterology, Hepatology, and Endocrinology, at the Hannover Medical School, discusses the real-world data of immunotherapy combinations in hepatocellular carcinoma.

Understanding irAEs Is Vital for IO Combo Use in HCC

October 05, 2021

In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.